FDA Oncology Announcements

Anti-EGFR × Head & Neck × Clear all

3 Announcements

FDA approves new dosing regimen for cetuximab

Drug: Erbitux (cetuximab) · Anti-EGFR antibody
Conditions: GastrointestinalHead & Neck

Cetuximab (Erbitux)

Drug: Erbitux (cetuximab) · Anti-EGFR antibody
Condition: Head & Neck

Erbitux (ceuximab) Approved for Use in Combination with Radiation Therapy

Drug: Erbitux (cetuximab) · Anti-EGFR antibody
Condition: Head & Neck